Switzerland EY’s Biotech Team Leader for the EMEIA region discusses the challenges Europe’s fragmented capital markets pose for biotech startups, the under-communicated benefits of doing an IPO on the Swiss stock exchange and the implications of the Actelion acquisition for the wider Swiss life sciences ecosystem. Among other things, you are…
Greece John Bouros CEO and founder of Alvion Pharmaceuticals in Greece on the opportunities inherent in any economic crisis, the growth of the Greek generics segment, and his strategy for growth; both domestic and international. Can you please start by telling us how your originally came to found Alvion back in…
Ireland Darren Cunningham tells us the story behind Inflection Biosciences (and its name), the rationale of focusing on small molecule cancer treatments, his thoughts on the Irish biotech start-up scene, and his hopes for the company’s future development. Can you first provide an introduction to Inflection Biosciences to our international audience? “The Irish…
Pharma Switzerland’s pharma industry is moving beyond staid conservatism and embracing risk in order to compete internationally and foster a new culture of innovation. Switzerland is frequently considered one of the most entrepreneurial and competitive countries in the world. As Thomas Cunei, secretary general of Interpharma, the association that represents 92…
Pharma Lyon provides companies with a flamboyant and collaborative environment to develop. Bruno Masurel, Head of the International Division of the local Chamber of Commerce talks about the advantages the region offers and the services the institution has to help companies go international. Could you please explain the reasons behind the…
Pharma Maikel Beerens, CEO and founder of Xilloc, a promising Dutch company that designs patient-specific implants, anatomical models and surgical guides for bone reconstruction or augmentation with the help of 3-D printing, explains how his company aims to provide patients worldwide with the tailor-made implants they deserve while reducing the overall socio-economic cost…
pharma The Netherlands provides a flourishing environment for biotech to grow. The vice president for European operations at Kite Pharma discusses how biotech start-ups can find their path to success and how Kite Pharma is looking at new innovative therapies for cancer treatment. Before joining T-Cell Factory, later acquired by Kite…
Alexion Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put in place, and how Alexion is communicating with patients’ associations and medical community to raise awareness about ultra-rare diseases. …
biotech The founder of this spin-off of the Autonomous University of the State of Morelos focusing on biologicals for human and veterinary use offers an overview of how the company came into life, the lack of culture at Mexican universities of filing patents for academic research and the potential of the…
biotech Bioceres manages investments in agricultural biotechnology and related sciences. The company’s CEO, Federico Trucco, discusses the potential of Argentina’s biotech scene to become a world-class drug developer in biopharma as well as Bioceres’ own investments in the sector. How did you become involved with Bioceres? I have known the…
medical devices The CEO and one of the founders of Lexel explains how the company adapts its medical devices to the specifications required by their international customers. Why did Lexel enter into the medical device market and most important, where did you see the opportunities when creating this company? From the…
Cell2B David Malta and Daniela Couto, Co-founders of Cell2B, discuss the company’s origins and plans to achieve market authorization, and what makes the fledgling company the partner of choice. What do you see as Portugal’s capacity for the local life sciences industry to grow? DM: Portugal is one of the best-positioned…
See our Cookie Privacy Policy Here